New research from U.S. Breast Cancer Surveillance Consortium (BCSC) members, including several University of Vermont researchers, found that from March to September 2020, breast biopsies and detected cancers at U.S. BCSC facilities dropped sharply, compared with the same span a year earlier.

With $3 million in support from a longtime major supporter of the University of Vermont Cancer Center, Randall F. Holcombe, M.D., M.B.A., was invested as the inaugural J. Walter Juckett Chair in Cancer Research in the Larner College of Medicine on November 3.

Linked to occupational asbestos exposure, malignant mesothelioma (MM) is an aggressive cancer arising primarily from the outer lining of the lungs with a dismal five-year survival rate of only five to 10 percent. Since 2004, only two therapies have been approved for the treatment of MM, which affects about 3,000 people a year in the United States. Now a promising new therapy for mesothelioma and metastatic cancer, arising from laboratory investigations at the University of Vermont, is about to enter a Phase I clinical trial.

Two members of the Larner College of Medicine community--Nick Lemon, information systems technical support staff member, and Katherine Strotmeyer, communications and community outreach director for the University of Vermont Cancer Center--were among the UVM stafff members who received a 2021 Our Common Ground award.

The University of Vermont Cancer Center hosted the 24th annual Women’s Health and Cancer Conference on October 1 from 7:30 a.m. to 2:30 p.m. The virtual event, which was free and open to the public, was sponsored by the Victoria Buffum Fund with an aim to empower and support individuals and communities with knowledge about cancer prevention, detection, treatment, and survivorship.

The National Cancer Institute (NCI) has awarded Noah Kolb, M.D., associate professor of neurological sciences at the University of Vermont's Larner College Medicine, and a team of researchers a $7 million grant to a develop a new intervention for chemo-induced neuropathy, one that can be as easily implemented in rural areas as large urban centers.

The FDA has revised the Emergency Use Authorizations (EUA) for both Pfizer and Moderna to authorize the use of a 3rd dose of COVID vaccine in the setting of immune compromised patients

(AUGUST 25, 2021) Randall Holcombe, M.D., M.B.A., director of the UVM Cancer Center and Juckett Professor of Cancer Research, commented on the role of mRNA in cancer treatment research.

Randall F. Holcombe, M.D., M.B.A., has been appointed director of the UVM Cancer Center (UVMCC) and chief of the Division of Hematology and Oncology in the Department of Medicine. Holcombe will officially begin his tenure August 1, 2021.

Sarah Nowak, Ph.D., and David Seward, M.D., Ph.D., were invested as the inaugural holders of a Huber Early Career Green and Gold Professorship of Pathology and Laboratory Medicine during a virtual ceremony March 30. UVM Professor of Pathology and Laboratory Medicine Emerita Sally Huber, Ph.D., established two separate Green and Gold professorships, one in honor of each of her parents, that will provide crucial funding to promising assistant professors who are likely to develop into successful, independent basic scientists or physician-scientists.

New findings, reported in Nature Communications and published by UVM researchers, describe the discovery of a unique dependence of cancer cells on a particular protein, which could lead to desperately-needed treatment for hard-to-treat cancers.